Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi

A. Santoro, R. Mazza, M. Spina, C. Califano, G. Specchia, M. Carella, U. Consoli, F. Palombi, M. Musso, A. Pulsoni, S. Kovalchuk, M. Bonfichi, F. Ricci, A. Fabbri, A.M. Liberati, M. Rodari, L. Giordano, E. Chimienti, M. Balzarotti, R. SorasioA. Gallamini, C. Ghiggi, P. Ciammella, U. Ricardi, S. Chauvie, C. Carlo-Stella, F. Merli

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi'. Together they form a unique fingerprint.

Medicine & Life Sciences